Global Pancreatic Cancer Diagnostic Market Top Major Players 2024, Forecast To 2033
8 Mar, 2024
The pancreatic cancer diagnostic market has experienced robust growth, expanding from $3.92 billion in 2023 to $4.21 billion in 2024, with a compound annual growth rate (CAGR) of 7.6%. This growth is attributed to advancements in genomic and molecular profiling, chemotherapy, and radiation therapy, along with increased research on pancreatic cancer genetics and awareness campaigns for early detection. Looking ahead, the market is projected to reach $5.74 billion by 2028, with a CAGR of 8.0%, driven by innovations such as liquid biopsy, targeted therapies, and artificial intelligence in diagnostics, as well as trends like immunotherapy research and advancements in imaging technologies.
Global Pancreatic Cancer Diagnostic Market Key Driver
The pancreatic cancer diagnostic market is poised for expansion due to the increasing prevalence of pancreatic cancer, attributed to factors such as smoking, diabetes, and genetic disorders. Early diagnosis is crucial for guiding treatment decisions and improving patient outcomes. According to the American Society of Clinical Oncology, pancreatic cancer is anticipated to affect 64,050 individuals in the United States in 2023, with a consistent annual increase in new cases. Therefore, the rising prevalence of pancreatic cancer is a significant driver of growth in the pancreatic cancer diagnostic market.
Get A Free Sample Of The Global Pancreatic Cancer Diagnostic Market ReportGlobal Pancreatic Cancer Diagnostic Market Segments
The pancreatic cancer diagnostic market covered in this report is segmented –
1) Product:Instruments, Consumables, Services
2) Treatment:Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy
3) Cancer Type:Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Colloid Carcinoma, Endocrine
4) Test Type:Imaging Test, Biopsy, Blood Test, Genomic Test, Other Test Types
5) End-User:Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, Other End-Users
By Geography: The countries covered in the pancreatic cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the pancreatic cancer diagnostic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Pancreatic Cancer Diagnostic Industry Players
Pfizer Inc.; Hitachi Medical Corporation; F. Hoffmann-La Roche AG; Novartis AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca plc; Abbott Laboratories Inc.; Danaher Corporation; Siemens Healthcare GmbH; FUJIFILM Corporation; Becton Dickinson and Company; Koninklijke Philips N.V.; GE Healthcare Bio Sciences AB; Laboratory Corporation of America Holdings; Agilent Technologies Inc.; Illumina Inc.; Qiagen Inc.; Myriad Genetics Inc.; Canon Medical Systems Corporation; Biological Dynamics Inc.; Berg LLC; Abcodia Ltd.; Acobiom; Amplified Sciences LLC; Avant Diagnostics Inc.; Axim Biotechnologies Inc.; Alaunus Biosciences Inc.; Advanced Marker Discovery SL; Anixa Diagnostics Corporation
Get The Full Global Pancreatic Cancer Diagnostic Market Report
Pancreatic Cancer Diagnostic Market Overview
Pancreatic cancer diagnostic refers to the procedures and methods for identifying, classifying, and staging pancreatic cancer with the goal of determining the condition, determining the severity of the disease, and directing treatment choices. It is commonly used to treat adenocarcinoma, squamous cell carcinoma, and insulinoma.